Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Andrew W. Roberts(The Royal Melbourne Hospital), John F. Seymour(The Royal Melbourne Hospital), Sari H. Enschede(AbbVie (United States)), Nikita Rudersdorf(AbbVie (United States)), Constantine S. Tam(Peter MacCallum Cancer Centre), Thomas J. Kipps(University of California San Diego), Danielle M. Brander(Duke University), Rod Humerickhouse(Abbott Fund), Matthew S. Davids(Harvard University), Jacqueline C. Barrientos(Northwell Health), Tanita Mason-Bright(AbbVie (United States)), Shuo Ma(Nantong University), Wijith Munasinghe(AbbVie (United States)), Ming Zhu(AbbVie (United States)), Mary Ann Anderson(The Royal Melbourne Hospital), Elisa Cerri(AbbVie (United States)), Jianning Yang(AbbVie (United States)), Lori A. Gressick(AbbVie (United States))
Cited by 44
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k